US Bancorp DE Grows Stake in Cardinal Health, Inc. $CAH

US Bancorp DE increased its holdings in shares of Cardinal Health, Inc. (NYSE:CAH) by 32.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 52,992 shares of the company’s stock after acquiring an additional 12,955 shares during the period. US Bancorp DE’s holdings in Cardinal Health were worth $10,890,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Aventura Private Wealth LLC purchased a new position in Cardinal Health during the 4th quarter valued at approximately $25,000. SJS Investment Consulting Inc. grew its holdings in Cardinal Health by 1,363.6% during the 3rd quarter. SJS Investment Consulting Inc. now owns 161 shares of the company’s stock valued at $25,000 after buying an additional 150 shares in the last quarter. Barnes Dennig Private Wealth Management LLC grew its holdings in Cardinal Health by 38.7% during the 4th quarter. Barnes Dennig Private Wealth Management LLC now owns 190 shares of the company’s stock valued at $39,000 after buying an additional 53 shares in the last quarter. JPL Wealth Management LLC purchased a new position in Cardinal Health during the 3rd quarter valued at approximately $31,000. Finally, Turning Point Benefit Group Inc. purchased a new position in Cardinal Health during the 3rd quarter valued at approximately $31,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health Price Performance

NYSE:CAH opened at $195.13 on Friday. The firm has a market capitalization of $45.92 billion, a price-to-earnings ratio of 29.84, a PEG ratio of 1.20 and a beta of 0.53. Cardinal Health, Inc. has a 1 year low of $137.75 and a 1 year high of $233.60. The business has a 50 day simple moving average of $213.73 and a 200-day simple moving average of $205.82.

Cardinal Health (NYSE:CAH) last posted its quarterly earnings data on Thursday, April 30th. The company reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.38. The business had revenue of $60.94 billion during the quarter, compared to analyst estimates of $62.10 billion. Cardinal Health had a negative return on equity of 92.61% and a net margin of 0.62%.The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the company earned $2.35 EPS. Cardinal Health has set its FY 2026 guidance at 10.700-10.80 EPS. As a group, analysts expect that Cardinal Health, Inc. will post 10.76 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Wednesday, April 1st were given a dividend of $0.5107 per share. The ex-dividend date of this dividend was Wednesday, April 1st. This represents a $2.04 dividend on an annualized basis and a yield of 1.0%. Cardinal Health’s payout ratio is 29.35%.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q3 non‑GAAP earnings beat estimates and company raised FY‑2026 guidance to $10.70–$10.80, above consensus — the core bullish catalyst. PR Newswire: Q3 Results & Outlook
• Positive Sentiment: Company executed $250M additional share repurchase (bringing FY26 repurchases to $1.0B) and reduced debt — shareholder‑friendly actions that support the share price. PR Newswire: Buybacks & Debt Reduction
• Neutral Sentiment: Wells Fargo cut its price target from $256 to $245 but kept an “overweight” rating, signaling continued analyst confidence despite the trim. Benzinga: Wells Fargo PT Change
• Neutral Sentiment: Full earnings call and transcripts are available for investors who want details on segment performance and management commentary. Yahoo Finance: Earnings Transcript Seeking Alpha: Call Transcript
• Negative Sentiment: Revenue missed expectations ($60.9B reported vs. ~$62.1B est.), which prompted media coverage and short‑term selling pressure despite the EPS beat. Benzinga: Revenue Miss Coverage
• Negative Sentiment: GAAP results were weaker: GAAP operating earnings and GAAP EPS declined, driven in part by a $184M pre‑tax goodwill impairment in the Navista & ION reporting unit — a one‑time charge that reduces headline profitability. PR Newswire: Goodwill Impairment
• Negative Sentiment: Several outlets highlighted the “mixed” nature of the report (EPS/guidance vs. revenue/GAAP weakness), which can increase volatility and keep some investors on the sidelines. CNBC: Mixed Results Coverage

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Citigroup cut their price target on Cardinal Health from $249.00 to $245.00 and set a “buy” rating for the company in a report on Friday. Zacks Research upgraded Cardinal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Wells Fargo & Company cut their price target on Cardinal Health from $256.00 to $245.00 and set an “overweight” rating for the company in a report on Friday. Leerink Partners restated an “outperform” rating and set a $275.00 price target on shares of Cardinal Health in a report on Monday, March 9th. Finally, Wall Street Zen upgraded Cardinal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.67.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.